Literature DB >> 18427546

P21-activated kinase is required for mitotic progression and regulates Plk1.

B Maroto1, M B Ye, K von Lohneysen, A Schnelzer, U G Knaus.   

Abstract

P21-activated kinases (Paks), a family of serine/threonine kinases, are effectors of the Rho GTPases Cdc42 and Rac1. Mammalian Pak1 and Pak homologs in simple eukaryotes are implicated in controlling G(2)/M transition and/or mitosis. Another serine/threonine kinase, polo-like kinase 1 (Plk1), is an important regulator of mitotic events, such as centrosome maturation, mitotic entry, spindle formation, sister chromatid cohesion and cytokinesis. Plk1 phosphorylation is thought to be one of the critical regulatory events leading to these Plk1-mediated functions. We show here that Pak1 is required for cell proliferation, mitotic progression and Plk1 activity in HeLa cells. Gain or loss of Pak function directly impacted phosphorylation and activity of Plk1. Phosphorylation of Plk1 on Ser 49 is important for metaphase-associated events. Inhibition of Pak activity leads to delay in G(2)/M progression and abnormal spindle formation, mirroring some attributes of Plk1 deregulation. Our results reveal a role for Pak in regulating Plk1 activity and mitotic progression, and connect Pak to the complex protein interaction network enabling cell division.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427546     DOI: 10.1038/onc.2008.131

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  The p21-activated kinase (PAK1) is involved in diet-induced beta cell mass expansion and survival in mice and human islets.

Authors:  Miwon Ahn; Stephanie M Yoder; Zhanxiang Wang; Eunjin Oh; Latha Ramalingam; Ragadeepthi Tunduguru; Debbie C Thurmond
Journal:  Diabetologia       Date:  2016-07-09       Impact factor: 10.122

Review 3.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

Review 4.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

5.  Prostate-derived sterile 20-like kinases (PSKs/TAOKs) are activated in mitosis and contribute to mitotic cell rounding and spindle positioning.

Authors:  Rachael L Wojtala; Ignatius A Tavares; Penny E Morton; Ferran Valderrama; N Shaun B Thomas; Jonathan D H Morris
Journal:  J Biol Chem       Date:  2011-06-24       Impact factor: 5.157

6.  Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells.

Authors:  Arminja N Kettenbach; Devin K Schweppe; Brendan K Faherty; Dov Pechenick; Alexandre A Pletnev; Scott A Gerber
Journal:  Sci Signal       Date:  2011-06-28       Impact factor: 8.192

7.  Cdk1-dependent mitotic enrichment of cortical myosin II promotes cell rounding against confinement.

Authors:  Subramanian P Ramanathan; Jonne Helenius; Martin P Stewart; Cedric J Cattin; Anthony A Hyman; Daniel J Muller
Journal:  Nat Cell Biol       Date:  2015-01-26       Impact factor: 28.824

8.  p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

Authors:  Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

9.  Knowledge based identification of essential signaling from genome-scale siRNA experiments.

Authors:  Armand Bankhead; Iliana Sach; Chester Ni; Nolwenn LeMeur; Mark Kruger; Marc Ferrer; Robert Gentleman; Carol Rohl
Journal:  BMC Syst Biol       Date:  2009-08-05

Review 10.  PAK signaling in oncogenesis.

Authors:  P R Molli; D Q Li; B W Murray; S K Rayala; R Kumar
Journal:  Oncogene       Date:  2009-05-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.